Beyond Air (NASDAQ: XAIR) completes up to $30M raise as FDA review continues
Rhea-AI Filing Summary
Beyond Air, Inc. (XAIR) reported results for the quarter ended June 30, 2026 and provided a corporate update. Revenue was $1.8 million, roughly flat year over year, while gross margin improved to 13% from 9%. Net loss attributable to common stockholders was $7.9 million, or $11.00 per share, compared with a loss of $7.7 million, or $30.67 per share, a year earlier.
As of June 30, 2026, cash, cash equivalents, restricted cash and marketable securities totaled $15.2 million, against $22.2 million of long-term debt and total liabilities of $30.1 million, leaving stockholders’ equity at $2.8 million. After quarter-end, the company completed an up to $30.1 million financing, including $10.2 million in upfront gross proceeds and up to an additional $20.0 million from potential warrant exercises. Management reaffirmed revenue guidance of $8 million for calendar 2026 and $16–$18 million for 2027, and highlighted ongoing FDA review of a PMA supplement for its second-generation LungFit PH system, with approval expected in the second half of 2026.
Positive
- Gross margin improved to 13% from 9% year over year, indicating better pricing or cost efficiency on existing revenue.
- Up to $30.1 million financing was secured after quarter-end, including $10.2 million upfront, which bolsters liquidity for commercial and international expansion.
- 2027 revenue guidance of $16–$18 million implies more than 110% year-over-year growth at the midpoint versus 2026 guidance.
- Regained compliance with Nasdaq’s minimum bid price requirement, reducing near-term listing risk.
Negative
- Net loss of $7.9 million for the quarter persisted, with only modest improvement versus the prior-year loss of $7.7 million.
- Stockholders’ equity fell to $2.8 million from $6.2 million at March 31, 2026, reflecting ongoing losses and a highly leveraged balance sheet.
- Interest and finance expense nearly tripled to $1.5 million from $0.5 million, increasing the drag from debt on results.
- Long-term debt of $22.2 million now exceeds total cash, cash equivalents, restricted cash and marketable securities of $15.2 million.
Insights
Analyzing...
8-K Event Classification
3 items: 2.02, 7.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Quarterly Revenue: $1,768,000
Gross Margin: 13%
Net Loss Attributable to Beyond Air, Inc.: $7,935,000
+5 more
8 metrics
Quarterly Revenue
$1,768,000
Revenue for the quarter ended June 30, 2026
Gross Margin
13%
Quarter ended June 30, 2026, versus 9% in prior-year quarter
Net Loss Attributable to Beyond Air, Inc.
$7,935,000
Quarter ended June 30, 2026
Cash, Cash Equivalents, Restricted Cash and Marketable Securities
$15,217,000
Total as of June 30, 2026
Long-Term Debt, Net
$22,167,000
Outstanding as of June 30, 2026
Upfront Gross Proceeds from Financing
$10,200,000
Portion of up to $30.1 million post-quarter financing
Total Potential Financing Size
$30,100,000
Recent financing including potential warrant exercises
Stockholders’ Equity
$2,839,000
Total stockholders’ equity as of June 30, 2026
Key Terms
PMA supplement, group purchasing organization, warrant liability, Discretionary Panel Monitor, +2 more
6 terms
PMA supplement medical
"Awaiting FDA review of the PMA supplement for the second-generation LungFit PH system"
A PMA supplement is a regulatory filing submitted to the U.S. Food and Drug Administration to request approval for changes to a medical device that already has premarket approval. Think of it like asking permission to alter a trusted product’s recipe, packaging, or manufacturing process; the agency reviews whether the change affects safety or performance. For investors, the outcome influences how quickly a modified product can be sold, the cost and risk of bringing updates to market, and potential sales or liability impacts.
group purchasing organization financial
"Entered into a national group purchasing agreement with a leading U.S. group purchasing organization"
A group purchasing organization (GPO) is an entity that helps a group of buyers, such as healthcare providers or businesses, combine their purchasing power to buy goods or services at lower prices. By negotiating on behalf of its members, a GPO can secure better deals than individual buyers could on their own. This can lead to cost savings and operational efficiencies, making GPOs important players in industries where large-scale purchasing influences overall expenses and profitability.
warrant liability financial
"Warrant liability | | | 1 | | | | 2"
Warrant liability is the financial obligation a company records when it grants warrants—special options giving the holder the right to buy company shares at a set price in the future. It matters to investors because changes in this liability can affect a company's reported earnings and overall financial health, similar to how a pending contract can influence a company's future value.
Discretionary Panel Monitor regulatory
"including compliance with the terms of the Discretionary Panel Monitor"
A discretionary panel monitor is a compliance mechanism—either a small oversight group or a software tool—that reviews and checks trades made at a manager’s discretion to ensure they follow investment rules, risk limits and client instructions. For investors it matters because this watchdog helps prevent unauthorized or risky decisions, reduces the chance of loss or regulatory penalties, and protects trust much like a referee or speed governor keeps a game or machine within safe limits.
Form 10-K/T regulatory
"expects to report financial results for the nine-month transition period ending December 31, 2026 on a Form 10-K/T"
hypoxic respiratory failure medical
"LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure"
A serious medical condition where the body is not getting enough oxygen into the blood despite breathing, like a plumbing system that can’t deliver enough water to the taps. It matters to investors because treatments, devices, or hospital stays tied to this condition can drive drug trial outcomes, regulatory approvals, patient volumes and healthcare costs, all of which affect revenue forecasts and company valuation.
Earnings Snapshot
Revenue: $1,768,000 · Guidance included
Quarter ended June 30, 2026
Revenue
$1,768,000
$8,000 increase vs $1,760,000 in prior-year quarter
Gross Margin
13%
Improved from 9% in prior-year quarter
Net Loss Attributable to Beyond Air, Inc.
$7,935,000
$244,000 higher loss vs $7,691,000 in prior-year quarter
Operating Expenses
$6,837,000
$936,000 decrease vs $7,773,000 in prior-year quarter
Cash and Investments
$15,217,000
Total cash, cash equivalents, restricted cash and marketable securities at June 30, 2026
Guidance
Reaffirmed revenue guidance of $8 million for calendar 2026 and $16–$18 million for 2027, with 2027 midpoint implying more than 110% year-over-year growth versus 2026 guidance.
FAQ
How much revenue did Beyond Air (XAIR) report for the quarter ended June 30, 2026?
Beyond Air reported $1.8 million in revenue for the quarter ended June 30, 2026, essentially flat with $1.76 million a year earlier. This modest top-line base supports its guidance but still reflects an early-stage commercial profile.
What was Beyond Air’s (XAIR) net loss and EPS for the June 30, 2026 quarter?
Beyond Air reported a net loss attributable to common stockholders of $7.9 million, or $11.00 per basic and diluted share. This compares with a net loss of $7.7 million, or $30.67 per share, in the prior-year quarter.
What is Beyond Air’s (XAIR) cash position and debt as of June 30, 2026?
As of June 30, 2026, Beyond Air held $15.2 million in cash, cash equivalents, restricted cash and marketable securities. Long-term debt was $22.2 million, and total liabilities were $30.1 million, resulting in $2.8 million of total stockholders’ equity.
What revenue guidance has Beyond Air (XAIR) provided for 2026 and 2027?
Beyond Air reaffirmed revenue guidance of $8 million for calendar 2026 and $16–$18 million for 2027. The 2027 range represents more than 110% year-over-year growth at the midpoint compared with 2026 guidance, assuming successful commercial execution.
What recent financing did Beyond Air (XAIR) complete and how large is it?
Beyond Air completed an up to $30.1 million financing after quarter-end. It received $10.2 million in upfront gross proceeds, with up to an additional $20.0 million possible from the exercise of short- and long-term warrants, some tied to FDA approval milestones.
What are the key regulatory milestones for Beyond Air’s (XAIR) LungFit PH system?
The FDA is reviewing a PMA supplement for the second-generation LungFit PH system, submitted in June 2025, with approval expected in the second half of 2026. International submissions for LungFit PH are also progressing with local partners.
Is Beyond Air (XAIR) changing its fiscal year, and how will it report?
Beyond Air is transitioning its fiscal year end from March 31 to December 31, effective December 31, 2026. It expects to report results for the nine-month transition period ending December 31, 2026 on a Form 10-K/T.
AI-generated analysis. How Rhea-AI works. Not financial advice.
